URD12: A urea derivative with marked antitumor activities

Oncology Letters

Volumn 3, Issue 2, 2012, Pages 373-376

  Wang, Ai Yun ^a,b   Lu, Yin ^b   Zhu, Hai Liang ^a   Jiao, Qing Cai ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Antitumor; Immune; Morpholine; Urea derivative

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; UNCLASSIFIED DRUG; URD12; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; FEASIBILITY STUDY; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; MOUSE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; SPLEEN; STOMACH CARCINOMA; THYMUS; TUMOR VOLUME;

EID: 84855234795     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.474     Document Type: Article

References (21)

1. Hackbarth CJ, Chen DZ, Lewis JG, et al: N-alkyl urea hydrox-amic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother 46: 2752-2764, 2002.
2. Yang J, Di F, He R, et al: Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients. Chin Med J (Engl) 116: 785-787, 2003.
3. Cook JW, Sterman DH, Singhal S, Smythe WR and Kaiser LR: Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models. Lung Cancer 42: 263-274, 2003.
4. Easmon J, Purstinger G, Heinisch G, et al: Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II) complexes of (4)N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines. J Med Chem 44: 2164-2171, 2001.
5. Fujita F, Fujita M, Inaba H, Sugimoto T, Okuyama Y and Taguchi T: [Combination chemotherapy of HO-221, a derivative of benzoylphenylurea with various anticancer agents against human cancer xenografts in nude mice]. Gan To Kagaku Ryoho 18: 2263-2270, 1991.
6. Gnewuch CT and Sosnovsky G: A critical appraisal of the evolution of N-nitrosoureas as anticancer drugs. Chem Rev 97: 829-1014, 1997.
7. Jiang JD, Denner L, Ling YH, et al: Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand. Cancer Res 62: 6080-6088, 2002.
8. Jiang JD, Roboz J, Weisz I, et al: Synthesis, cancericidal and antimicrotubule activities of 3-(haloacetamido)-benzoylureas. Anticancer Drug Des 13: 735-747, 1998.
9. Okada H, Koyanagi T and Yamada N: Synthesis and antitumor activities of prodrugs of benzoylphenylureas. Chem Pharm Bull (Tokyo) 42: 57-61, 1994.
10. Olaharski AJ, Mondrala ST and Eastmond DA: Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin. Mutat Res 582: 79-86, 2005.
11. Singh SK, Ruchelman AL, Li TK, Liu A, Liu LF and LaVoie EJ: Nitro and amino substitution in the D-ring of 5-(2- dimethyl-aminoethyl)-2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naph-thyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. J Med Chem 46: 2254-2257, 2003.
12. Toth JE, Grindey GB, Ehlhardt WJ, et al: Sulfonimidamide analogs of oncolytic sulfonylureas. J Med Chem 40: 1018-1025, 1997.
13. Cao P, Huang XF, Ding H, et al: Synthesis and cytotoxic evaluation of substituted urea derivatives as inhibitors of human-leukemia K562 cells. Chem Biodivers 4: 881-886, 2007.
14. Si-Tu ZQ and Wu JZ (eds): Cell Culture. 2nd edition. World Publishing Corporation, Xi'an, pp200-201, 2007.
15. Bliss C: The comparison of dosage-mortality data. Ann Appl Biol 22: 307-333, 1935.
16. Tian Z, Si J, Chang Q, et al: Antitumor activity and mechanisms of action of total glycosides from aerial part of Cimicifuga dahurica targeted against hepatoma. BMC Cancer 7: 237, 2007.
17. Long L and Li Q: The effect of alkaloid from Oxytropis ochrocephala on growth inhibition and expression of PCNA and p53 in mice bearing H22 hepatocellular carcinoma. Yakugaku Zasshi 125: 665-670, 2005.
18. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
19. Hirohashi S, Shimosato Y, Kameya T, et al: Production of alpha-fetoprotein and normal serum proteins by xenotransplanted human hepatomas in relation to their growth and morphology. Cancer Res 39: 1819-1828, 1979.
20. Srivastava JK and Gupta S: Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. Biochem Biophys Res Commun 346: 447-453, 2006.
21. Stolarska M, Mlynarski W, Zalewska-Szewczyk B and Bodalski J: Cytoprotective effect of amifostine in the treatment of childhood neoplastic diseases - a clinical study including the pharmacoeconomic analysis. Pharmacol Rep 58: 30-34, 2006.